Clinical trials: Pulmonary Disease (COPD), Chronic Obstructive
Chronic Obstructive Pulmonary Disease
Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary Disease
This study involves development and testing of a patient and family-centered transitional care program for patients who are hospitalized with Chronic Obstructive Pulmonary Disease (COPD) exacerbations.
- Trial name
- BREATHE (NCT02036294)
- Testing
- BREATHE program, Usual Care
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Johns Hopkins University
Pulmonary Disease, Chronic Obstructive
Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece
The primary objective of this non-interventional study (NIS) is to evaluate changes within 3 months in quality of life according to health status evaluated with the COPD Assessment Test (CAT) in COPD patients who have recently…
- Trial name
- NCT04672941
- Testing
- Tiotropium bromide plus Olodaterol
- Where
- 2 sites in Greece
- Volunteers
- 1,396 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive, Chronic Bronchitis
Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients
The primary objective is to comparatively evaluate the isolated effects of a long-acting beta2-adrenergic (formoterol fumarate 12µg b.i.d.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Chronic Bronchitis, Pulmonary Emphysema
- Trial name
- NCT00680056
- Testing
- Formoterol plus Tiotropium
- Where
- Brazil
- Volunteers
- 33 people
- Sponsor
- Federal University of São Paulo
Chronic Obstructive Pulmonary Disease
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- MOVE (NCT01996319)
- Testing
- QVA149
- Where
- 30 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
COPD, COPD Exacerbation
Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
This will be a non-blinded feasibility (pilot) study comparing triple therapy nebulizer vs dry powdered inhalers (DPI) for care transitions in Chronic obstructive pulmonary disease (COPD) exacerbation patients.
- Trial name
- NCT03219866
- Testing
- Nebulizers, Dry Powder Inhaler, Brovana
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Pulmonary Disease, Chronic Obstructive
A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COPD is characterized by an airflow limitation, which is not fully reversible, usually progressive and accompanied by chronic cough, sputum production and dyspnea, which can be a major cause of disability and anxiety associated…
- Trial name
- NCT03034915
- Testing
- UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS
- Where
- 212 sites in United States, Argentina and 10 more
- Volunteers
- 2,696 people
- Sponsor
- GlaxoSmithKline
Heart Failure, Coronary Artery Disease
COVID-19 Testing in Underserved and Vulnerable Populations
As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building project to…
- Conditions
- Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases
- Trial name
- NCT05315908
- Testing
- Community outreach method
- Where
- United States
- Volunteers
- 9,120 people
- Sponsor
- Jesse Nodora
Pulmonary Disease, Chronic Obstructive
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler®…
- Trial name
- NCT01694771
- Testing
- Tiotropium, Olodaterol
- Where
- 90 sites in United States
- Volunteers
- 1,134 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
Study to assess the long-term safety and effectiveness of Spiolto in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD) in real-world setting
- Trial name
- NCT02850978
- Testing
- Spiolto
- Where
- Japan
- Volunteers
- 1,335 people
- Sponsor
- Boehringer Ingelheim
COPD, Emphysema
Implementing and Evaluating the Genie Tool in COPD
The Generating Engagement in Network Involvement (GENIE) Tool is designed to support people to find and join social activities in their own neighbourhoods.
- Trial name
- GeCop (NCT02935452)
- Testing
- GENIE - social networking tool
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Southampton
Chronic Obstructive Pulmonary Disease
Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
To demonstrate the free combination of budesonide and indacaterol is as efficacious as fluticasone and salmeterol in patients with COPD
- Trial name
- COMBINE (NCT02055352)
- Testing
- Budesonide, Fluticasone, Indacaterol
- Where
- 25 sites in Argentina, Brazil and 6 more
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
- Trial name
- NCT02518139
- Testing
- TD-4208, Tiotropium
- Where
- United States
- Volunteers
- 1,060 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD
The primary objective of this trial is to establish superiority of the once-daily Tiotropium plus Salmeterol Inhalation Powder in daytime lung function response and non-inferiority in night-time lung function response over the…
- Trial name
- NCT00662792
- Testing
- Tiotropium (Tio18GEL), Salmeterol MDPI (Salm50DPI), Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)
- Where
- 12 sites in Germany
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
- Trial name
- NCT01023516
- Testing
- AZD9668
- Where
- 66 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
To investigate whether Budesonide/Formoterol (Symbicort ®) therapy can improve heart function at rest by decreasing lung hyperinflation in patients with COPD (Chronic Obstructive Pulmonary Disease).
- Trial name
- AZCO (NCT01760304)
- Testing
- Budesonide / Formoterol
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Disease, Chronic Obstructive
Digihaler in Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics [peak inspiratory flow (PIF), inhalation volume, number of inhalation events] amongst COPD patients in the ambulatory setting.
- Trial name
- NCT05241288
- Testing
- Albuterol eMDPI DS
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Does tiotropium effect the cough reflex in patients with COPD and chronic bronchitis.
- Trial name
- NCT00870896
- Testing
- Tiotropium
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- ThomasTruncale
Pulmonary Disease, Chronic Obstructive
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
- Trial name
- COPD (NCT01323660)
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 307 people
- Sponsor
- GlaxoSmithKline
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)
The purpose of this study was to evaluate the effect of ION-827359 on forced expiratory volume in 1 second (FEV1) in participants with mild to moderate COPD with CB.
- Trial name
- NCT04441788
- Testing
- ION-827359
- Where
- 15 sites in Czechia, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD.
- Trial name
- NCT00676052
- Testing
- GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg
- Where
- 88 sites in United States, Argentina and 12 more
- Volunteers
- 576 people
- Sponsor
- GlaxoSmithKline